Other News To Note
Wednesday, June 13, 2012
Affiris AG, of Vienna, Austria, initiated a global Phase I trial of its Parkinson's vaccine candidate, PD01A. The vaccine is directed against alpha-synuclein, a protein thought to cause the onset and progression of the disease, and it aims to educate the immune system to generate antibodies directed against the protein. The trial, being conducted in Vienna, involves up to 32 patients, with primary endpoints of safety and tolerability.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.